Vertex Pharmaceuticals Incorporated

Headquarters: Boston, MA, United States

Founded: 1989

Employees: 3,900

CEO: Dr. Reshma Kewalramani FASN, M.D.


Market Cap

$107.23 Billion

USD as of Jan. 1, 2024

Market Cap History

Company Description

Vertex Pharmaceuticals Incorporated is a pharmaceuticals and biotherapeutics company. It notably produces drugs and genetic therapies for cystic fibrosis and other skin conditions, such as pain, sickle cell disease, beta-thalassemia, hormonal deficiencies, kidney diseases, Duchenne muscular dystrophy, and diabetes.

Vertex Pharmaceuticals Incorporated market capitalization over time

Evolution of Vertex Pharmaceuticals Incorporated market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Vertex Pharmaceuticals Incorporated

Detailed Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Top 1-year algo backtest: +181.22%

$10,000 in June 2023 would now be $28,122 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Vertex Pharmaceuticals Incorporated has the following listings and related stock indices.

Stock: NASDAQ: VRTX wb_incandescent

Stock: FSX: VX1 wb_incandescent

Product & Services


Key People

Reshma Kewalramani, M. D., president and CEO Stuart A. Arbuckle, executive vice president and chief commercial officer Michael J. Parini, executive vice president and chief legal, administrative and business development officer Jeffrey Leiden, M. D., Ph D, executive chairman David Altshuler, M. D., Ph D, executive vice president, global research and chief scientific officer Amit K. Sachdev, executive vice president and chief patient officer


Revenue: US$3.04 billion (2018)



50 Northern Avenue

Boston, MA 02210

United States

Phone: 617 341 6100